Despite headline-grabbing controversies over the high cost of cancer, hepatitis C and other drugs in the U.S., the path to a projected $1.4 trillion in global total spending on medicines in 2020 will be driven not just by pricey prescriptions in developed markets, but also by increased access to medicines in low- and middle-income countries, according to a new report by the IMS Institute for Healthcare Informatics.